Clinical images: Multi‐modality imaging monitoring of anti–tumor necrosis factor α treatment at the joint and skin level in psoriatic arthritis

Publisher： John Wiley & Sons Inc

E-ISSN： 1529-0131|62|12|3829-3829

ISSN： 0004-3591

Source： Arthritis & Rheumatism, Vol.62, Iss.12, 2010-12, pp. : 3829-3829

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Targeting tumor necrosis factor α in psoriasis and psoriatic arthritis

By Fantuzzi Francesca Del Giglio Micol Gisondi Paolo Girolomoni Giampiero

Expert Opinion on Therapeutic Targets, Vol. 12, Iss. 9, 2008-09 ,pp. : 1085-1096

Informa Healthcare

Access to resources Recommend Favorite

A Threshold Hazard Model for Estimating Serious Infection Risk Following Anti-Tumor Necrosis Factor Therapy in Rheumatoid Arthritis Patients

By Fu Bo Lunt Mark Galloway James Dixon Will Hyrich Kimme Symmons Deborah

Journal of Biopharmaceutical Statistics, Vol. 23, Iss. 2, 2013-03 ,pp. : 461-476

Taylor & Francis Ltd

Access to resources Recommend Favorite

Pharmacogenomics of tumor necrosis factor antagonists in rheumatoid arthritis

By Ranganathan Prabha

Pharmacogenomics, Vol. 6, Iss. 5, 2005-07 ,pp. : 481-490

Future Medicine

Access to resources Recommend Favorite

The Case of Tumour Necrosis Factor-α Inhibitors in the Treatment of Rheumatoid Arthritis: A Budget Impact Analysis

By Sørensen Jan

PharmacoEconomics, Vol. 23, Iss. 3, 2005-01 ,pp. : 289-298

Adis International

Access to resources Recommend Favorite

A novel anti-fibrotic agent pirfenidone suppresses tumor necrosis factor- at the translational level

By Nakazato H. Oku H. Yamane S. Tsuruta Y. Suzuki R.

European Journal of Pharmacology, Vol. 446, Iss. 1, 2002-06 ,pp. : 177-185

Elsevier

Access to resources Recommend Favorite